SCHEMBL3317867

SCHEMBL3317867

Brc1ccc2nc(-c3ccccc3)c(-c3ccccc3)nc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.61
KDM4E B2RXH2 4/20 0.61
ALDH1A1 P00352 4/20 0.61
L3MBTL1 Q9Y468 3/20 0.61
ATM Q13315 3/20 0.61
TLR9 Q9NR96 1/20 0.61
PRNP P04156 1/20 0.57
GAA P10253 2/20 0.56
HPGD P15428 2/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
PIK3R1 P27986 1/20 0.54
PIK3CA P42336 1/20 0.54
TDP1 Q9NUW8 2/20 0.53
DCLK1 O15075 1/20 0.51
PRKD3 O94806 1/20 0.51
MAP4K4 O95819 1/20 0.51
CHEK2 O96017 1/20 0.51
CSF1R P07333 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29407052 0.88 ALDH1A1 (0.57) KMT2AKDM4EALDH1A1L3MBTL1ATM
SCHEMBL29406607 0.88 ALDH1A1 (0.57) KMT2AKDM4EALDH1A1L3MBTL1ATM
SCHEMBL12317104 0.87 ALDH1A1 (0.56) KMT2AKDM4EALDH1A1L3MBTL1ATM
SCHEMBL650086 0.83 L3MBTL1 (0.64) KMT2AKDM4EALDH1A1L3MBTL1ATM
SCHEMBL30476324 0.83 L3MBTL1 (0.64) KMT2AKDM4EALDH1A1L3MBTL1ATM
SCHEMBL21281903 0.82 L3MBTL1 (0.53) KMT2AKDM4EALDH1A1L3MBTL1ATM
SCHEMBL1301829 0.81 ALDH1A1 (0.68) KMT2AKDM4EALDH1A1L3MBTL1ATM
SCHEMBL28478677 0.81 KDM4E (0.57) KMT2AKDM4EALDH1A1L3MBTL1ATM
SCHEMBL31070203 0.81 MAPK14 (0.51) KMT2AKDM4EALDH1A1L3MBTL1ATM
SCHEMBL18647352 0.81 PRNP (0.62) KMT2AALDH1A1L3MBTL1ATMPRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120192275-A Cyclobutadiene-containing luminescent material, preparation method and application 深圳大学 2025-06-24 CN disclosed
CN-118420551-A Method for synthesizing quinoxaline compound by catalytic synthesis of cyclopentadienyl titanium complex 宁夏师范学院 2024-08-02 CN disclosed
CN-114380803-B Spirobifluorene compound, electron transport composition, and organic electroluminescent device 常州强力电子新材料股份有限公司 2024-07-12 CN disclosed
WO-2023160187-A1 CARBAZOLE DERIVATIVE AND USE THEREOF 上海八亿时空先进材料有限公司 2023-08-31 WO disclosed
WO-2023138254-A1 HETEROCYCLIC COMPOUND, AND ORGANIC ELECTROLUMINESCENT MATERIAL AND ELEMENT 上海八亿时空先进材料有限公司 2023-07-27 WO disclosed
CN-116217557-A Dibenzofuran-containing compound and organic electroluminescent element 常州强力昱镭光电材料有限公司 2023-06-06 CN disclosed
CN-114380803-A Spirobifluorene compound, electron transport composition and organic electroluminescent device 常州强力昱镭光电材料有限公司 2022-04-22 CN disclosed
CN-111116496-B Synthetic method of quinoxaline heterocyclic derivative 扬州大学 2021-12-31 CN disclosed
CN-111187225-B Condensed ring aromatic hydrocarbon derivative with quinoxaline group and application thereof 北京鼎材科技有限公司 2021-06-11 CN disclosed
CN-110386925-B Bipolar molecule derivative for organic light-emitting element 祥德科技股份有限公司 2021-04-02 CN disclosed
US-9353065-B2 Heterocyclic bridged biphenyls BASF SE (DE) 2016-05-31 US disclosed
US-9353065-B2 Heterocyclic bridged biphenyls BASF SE (DE) 2016-05-31 US disclosed
EP-2125752-B1 HETEROCYCLIC BRIDGED BIPHENYLS BASF SE (DE) 2015-08-12 EP disclosed
EP-2125752-B1 HETEROCYCLIC BRIDGED BIPHENYLS BASF SE (DE) 2015-08-12 EP disclosed
US-20100109514-A1 HETEROCYCLIC BRIDGED BIPHENYLS UDC IRELAND LIMITED (IE) 2010-05-06 US disclosed
US-20100109514-A1 HETEROCYCLIC BRIDGED BIPHENYLS UDC IRELAND LIMITED (IE) 2010-05-06 US disclosed
US-20100109514-A1 HETEROCYCLIC BRIDGED BIPHENYLS UDC IRELAND LIMITED (IE) 2010-05-06 US disclosed
EP-2125752-A1 HETEROCYCLIC BRIDGED BIPHENYLS BASF SE (DE) 2009-12-02 EP disclosed
WO-2008119666-A1 HETEROCYCLIC BRIDGED BIPHENYLS BASF SE (CH) 2008-10-09 WO disclosed
WO-2008119666-A1 HETEROCYCLIC BRIDGED BIPHENYLS BASF SE (CH) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100109514-A1 HETEROCYCLIC BRIDGED BIPHENYLS OCIAD1, SBDS, OCIAD2 KMT2A 3605/4885KDM4E 3206/4885ALDH1A1 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.